• Sadelain M.

CD19 CAR T cells.

Cell. 2017; 171: 1471

• Raje N.
• et al.

Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma.

N. Engl. J. Med. 2019; 380: 1726-1737

• Mullard A.

FDA approves 100th monoclonal antibody product.

Nat. Rev. Drug Discov. 2021; 20: 491-495

• Ghorashian S.
• et al.

Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR.

Nat. Med. 2019; 25: 1408-1414

• Caserta S.
• et al.

Reduced functional avidity promotes central and effector memory CD4 T cell responses to tumor-associated antigens.

J. Immunol. 2010; 185: 6545-6554

• Xu X.
• et al.

Mechanisms of relapse after CD19 CAR T-cell therapy for acute lymphoblastic leukemia and its prevention and treatment strategies.

Front. Immunol. 2019; 10: 2664-2674

• Shah N.N.
• Fry T.J.

Mechanisms of resistance to CAR T cell therapy.

Nat. Rev. Clin. Oncol. 2019; 16: 372-385

• Watanabe K.
• et al.

Expanding the therapeutic window for CAR T cell therapy in solid tumors: the knowns and unknowns of CAR T cell biology.

Front. Immunol. 2018; 9: 2486

• Cheever M.A.
• et al.

The prioritization of cancer antigens: a National Cancer Institute pilot project for the acceleration of translational research.

Clin. Cancer Res. 2009; 15: 5323-5337

• Sun S.
• et al.

Immunotherapy with CAR-modified T cells: toxicities and overcoming strategies.

J Immunol Res. 2018; 2018: 2386187

• Hirayama A.V.
• Turtle C.J.

Toxicities of CD19 CAR-T cell immunotherapy.

Am. J. Hematol. 2019; 94: S42-S49

• Mamonkin M.
• et al.

A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies.

Blood. 2015; 126: 983-992

• Liu X.
• et al.

Driving better and safer HER2-specific CARs for cancer therapy.

Oncotarget. 2017; 8: 62730-62741

• Morgan R.A.
• et al.

Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2.

Mol. Ther. 2010; 18: 843-851

• Solouki S.
• et al.

TCR signal strength and antigen affinity regulate CD8(+) memory T cells.

J. Immunol. 2020; 205: 1217-1227

• Zehn D.
• et al.

Complete but curtailed T-cell response to very low-affinity antigen.

Nature. 2009; 458: 211-214

• Drent E.
• et al.

Combined CD28 and 4-1BB costimulation potentiates affinity-tuned chimeric antigen receptor–engineered T cells.

Clin. Cancer Res. 2019; 25: 4014

• Liu X.
• et al.

Affinity-tuned ErbB2 or EGFR chimeric antigen receptor T cells exhibit an increased therapeutic index against tumors in mice.

Cancer Res. 2015; 75: 3596

• Drent E.
• et al.

A rational strategy for reducing on-target off-tumor effects of CD38-chimeric antigen receptors by affinity optimization.

Mol. Ther. 2017; 25: 1946-1958

• Chmielewski M.
• et al.

T cell activation by antibody-like immunoreceptors: increase in affinity of the single-chain fragment domain above threshold does not increase T cell activation against antigen-positive target cells but decreases selectivity.

J. Immunol. 2004; 173: 7647

• Arcangeli S.
• et al.

Balance of anti-CD123 chimeric antigen receptor binding affinity and density for the targeting of acute myeloid leukemia.

Mol. Ther. 2017; 25: 1933-1945

• Song D.-G.
• et al.

A fully human chimeric antigen receptor with potent activity against cancer cells but reduced risk for off-tumor toxicity.

Oncotarget. 2015; 6: 21533-21546

• Caruso H.G.
• et al.

Tuning sensitivity of CAR to EGFR density limits recognition of normal tissue while maintaining potent antitumor activity.

Cancer Res. 2015; 75: 3505-3518

• Richman S.A.
• et al.

High-affinity GD2-specific CAR T cells induce fatal encephalitis in a preclinical neuroblastoma model.

Cancer Immunol. Res. 2018; 6: 36-46

• Maus M.V.
• et al.

An MHC-restricted antibody-based chimeric antigen receptor requires TCR-like affinity to maintain antigen specificity.

Mol. Ther. Oncolytics. 2016; 3: 1-9

• Roddie C.
• et al.

Durable responses and low toxicity after fast off-rate CD19 chimeric antigen receptor-T therapy in adults with relapsed or refractory B-cell acute lymphoblastic leukemia.

J. Clin. Oncol. 2021; 39 (JCO2100917): 3352-3363

• Gogishvili T.
• et al.

SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7(+) normal lymphocytes.

Blood. 2017; 130: 2838-2847

• Szöőr Á.
• et al.

Trastuzumab derived HER2-specific CARs for the treatment of trastuzumab-resistant breast cancer: CAR T cells penetrate and eradicate tumors that are not accessible to antibodies.

Cancer Lett. 2020; 484: 1-8

• Chen X.
• et al.

Rational tuning of CAR tonic signaling yields superior T-cell therapy for cancer.

bioRxiv. 2020; (2020.10.01.322990)

• Caruana I.
• et al.

From monoclonal antibodies to chimeric antigen receptors for the treatment of human malignancies.

Semin. Oncol. 2014; 41: 661-666

• Abbott R.C.
• et al.

Novel high-affinity EGFRvIII-specific chimeric antigen receptor T cells effectively eliminate human glioblastoma.

Clin. Transl. Immunol. 2021; 10e1283

• Xu J.L.
• Davis M.M.

Diversity in the CDR3 region of V(H) is sufficient for most antibody specificities.

Immunity. 2000; 13: 37-45

• D’Angelo S.
• et al.

Many routes to an antibody heavy-chain CDR3: necessary, yet insufficient, for specific binding.

Front. Immunol. 2018; 9: 395

• Simons J.F.
• et al.

Affinity maturation of antibodies by combinatorial codon mutagenesis versus error-prone PCR.

MAbs. 2020; 12: 1803646

• Cirino P.C.
• et al.

Generating mutant libraries using error-prone PCR.

in: Arnold F.H. Georgiou G. Directed Evolution Library Creation: Methods and Protocols. Humana Press, 2003: 3-9

• Wilson D.S.
• Keefe A.D.

Random mutagenesis by PCR.

Curr. Protoc. Mol. Biol. 2001; 51 (Chapter 8, Unit 8.3): 8.3.1-8.3.9

• Liu B.
• et al.

Improving the mutagenesis efficiency of the Kunkel method by codon optimization and annealing temperature adjustment.

New Biotechnol. 2020; 56: 46-53

• Maruthachalam B.V.
• et al.

A single-framework synthetic antibody library containing a combination of canonical and variable complementarity-determining regions.

ChemBioChem. 2017; 18: 2247-2259

• Kunkel T.A.

Rapid and efficient site-specific mutagenesis without phenotypic selection.

Proc. Natl. Acad. Sci. U. S. A. 1985; 82: 488-492

• Tundidor Y.
• et al.

Affinity-matured variants derived from nimotuzumab keep the original fine specificity and exhibit superior biological activity.

Sci. Rep. 2020; 10: 1194

• Chang A.
• et al.

A novel phage display vector for selection of target-specific peptides.

Protein Eng. Des. Sel. 2020; 33

• Huang R.
• et al.

Improvements to the Kunkel mutagenesis protocol for constructing primary and secondary phage-display libraries.

Methods. 2012; 58: 10-17

• Rouet R.
• et al.

Generation of human single domain antibody repertoires by Kunkel mutagenesis.

Methods Mol. Biol. 2012; 907: 195-209

• Marks J.D.
• et al.

By-passing immunization: building high affinity human antibodies by chain shuffling.

Bio/Technology. 1992; 10: 779-783

• Wijesuriya S.D.
• et al.

Antibody engineering to improve manufacturability.

Protein Expr. Purif. 2018; 149: 75-83

• Weiss G.A.
• et al.

Rapid mapping of protein functional epitopes by combinatorial alanine scanning.

Proc. Natl. Acad. Sci. U. S. A. 2000; 97: 8950-8954

• Marimuthu P.
• Singaravelu K.

Prediction of hot spots at myeloid cell leukemia-1–inhibitor interface using energy estimation and alanine scanning mutagenesis.

Biochemistry. 2018; 57: 1249-1261

• Robin G.
• et al.

Restricted diversity of antigen binding residues of antibodies revealed by computational alanine scanning of 227 antibody–antigen complexes.

J. Mol. Biol. 2014; 426: 3729-3743

• Heinemann P.M.
• et al.

Active-site loop variations adjust activity and selectivity of the cumene dioxygenase.

Nat. Commun. 2021; 12: 1095

• Kim D.
• et al.

Molecular characterization of single-chain antibody variable fragments (scFv) specific to Pep27 from Streptococcus pneumoniae.

Biochem. Biophys. Res. Commun. 2018; 501: 718-723

• Yamashita T.
• et al.

Affinity improvement of a cancer-targeted antibody through alanine-induced adjustment of antigen-antibody interface.

Structure. 2019; 27: 519-527.e5

• Zoller M.J.

New molecular biology methods for protein engineering.

Curr. Opin. Biotechnol. 1991; 2: 526-531

• Öling D.
• et al.

Large scale synthetic site saturation GPCR libraries reveal novel mutations that alter glucose signaling.

ACS Synth. Biol. 2018; 7: 2317-2321

• Lippow S.M.
• et al.

Computational design of antibody-affinity improvement beyond in vivo maturation.

Nat. Biotechnol. 2007; 25: 1171-1176

• Tue-ngeun P.
• et al.

Improved scFv anti-HIV-1 p17 binding affinity guided from the theoretical calculation of pairwise decomposition energies and computational alanine scanning.

Biomed. Res. Int. 2013; 2013: 713585

• Warszawski S.
• et al.

Optimizing antibody affinity and stability by the automated design of the variable light-heavy chain interfaces.

PLoS Comput. Biol. 2019; 15: e1007207

• Baran D.
• et al.

Principles for computational design of binding antibodies.

Proc. Natl. Acad. Sci. 2017; 114: 10900

• Norman R.A.
• et al.

Computational approaches to therapeutic antibody design: established methods and emerging trends.

Brief. Bioinform. 2019; 21: 1549-1567

• Hoogenboom H.R.

Selecting and screening recombinant antibody libraries.

Nat. Biotechnol. 2005; 23: 1105-1116

• Lad L.
• et al.

High-throughput kinetic screening of hybridomas to identify high-affinity antibodies using bio-layer interferometry.

J. Biomol. Screen. 2015; 20: 498-507

• Valldorf B.
• et al.

Antibody display technologies: selecting the cream of the crop.

Biol. Chem. 2021;

• Ljungars A.
• et al.

Deep mining of complex antibody phage pools generated by cell panning enables discovery of rare antibodies binding new targets and epitopes.

Front. Pharmacol. 2019; 10: 847

• Dyson M.R.
• et al.

Beyond affinity: selection of antibody variants with optimal biophysical properties and reduced immunogenicity from mammalian display libraries.

mAbs. 2020; 12: 1829335

• Boder E.T.
• et al.

Engineering antibodies by yeast display.

Arch. Biochem. Biophys. 2012; 526: 99-106

• Bazan J.
• et al.

Phage display—a powerful technique for immunotherapy: 1. Introduction and potential of therapeutic applications.

Hum. Vaccin. Immunother. 2012; 8: 1817-1828

• Zahnd C.
• et al.

Ribosome display: selecting and evolving pr
oteins in vitro that specifically bind to a target.

Nat. Methods. 2007; 4: 269-279

• Jost C.
• et al.

CAR-J cells for antibody discovery and lead optimization of TCR-like immunoglobulins.

MAbs. 2020; 12: 1840709

• Ochi T.
• et al.

A single-chain antibody generation system yielding CAR-T cells with superior antitumor function.

Commun. Biol. 2021; 4: 273

• Beerli R.R.
• et al.

Isolation of human monoclonal antibodies by mammalian cell display.

Proc. Natl. Acad. Sci. 2008; 105: 14336-14341

• Ho M.
• Pastan I.

Mammalian cell display for antibody engineering.

Methods Mol. Biol. (Clifton, N.J.). 2009; 525: 337-xiv

• González P.A.
• et al.

T cell receptor binding kinetics required for T cell activation depend on the density of cognate ligand on the antigen-presenting cell.

Proc. Natl. Acad. Sci. U. S. A. 2005; 102: 4824-4829

• Roddie C.
• et al.

AUTO1, a novel fast off CD19CAR delivers durable remissions and prolonged CAR T cell persistence with low CRS or neurotoxicity in adult ALL.

Blood. 2019; 134: 226

• Govern C.C.
• et al.

Fast on-rates allow short dwell time ligands to activate T cells.

Proc. Natl. Acad. Sci. 2010; 107: 8724

• Hudecek M.
• et al.

Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells.

Clin. Cancer Res. 2013; 19: 3153

• Gilchuk P.
• et al.

Integrated pipeline for the accelerated discovery of antiviral antibody therapeutics.

Nat. Biomed. Eng. 2020; 4: 1030-1043

• Hua X.
• et al.

Competitive and noncompetitive phage immunoassays for the determination of benzothiostrobin.

Anal. Chim. Acta. 2015; 890: 150-156

• Wang J.
• et al.

Screening and identification of RhD antigen mimic epitopes from a phage display random peptide library for the serodiagnosis of haemolytic disease of the foetus and newborn.

Blood Transfus. 2019; 17: 53-59

• Yang X.
• et al.

Hapten synthesis and the development of an ultrasensitive indirect competitive ELISA for the determination of diethylstilbestrol in food samples.

Sci. Rep. 2020; 10: 3270

• Daigo K.
• et al.

A simple hybridoma screening method for high-affinity monoclonal antibodies using the signal ratio obtained from time-resolved fluorescence assay.

Anal. Biochem. 2006; 351: 219-228

• Peruski A.H.
• et al.

Rapid and sensitive detection of biological warfare agents using time-resolved fluorescence assays.

J. Immunol. Methods. 2002; 263: 35-41

• Xiong Y.
• et al.

Emerging strategies to enhance the sensitivity of competitive ELISA for detection of chemical contaminants in food samples.

TrAC Trends Anal. Chem. 2020; 126115861

• Geuijen C.A.
• et al.

Affinity ranking of antibodies using flow cytometry: application in antibody phage display-based target discovery.

J. Immunol. Methods. 2005; 302: 68-77

• Worthington J.E.
• et al.

A comparison of enzyme-linked immunoabsorbent assays and flow cytometry techniques for the detection of HLA specific antibodies.

Hum. Immunol. 2001; 62: 1178-1184

• Daugherty P.S.
• et al.

Flow cytometric screening of cell-based libraries.

J. Immunol. Methods. 2000; 243: 211-227

• Hemadou A.
• et al.

An innovative flow cytometry method to screen human scFv-phages selected by in vivo phage-display in an animal model of atherosclerosis.

Sci. Rep. 2018; 8: 15016

• Georgiou G.

Analysis of large libraries of protein mutants using flow cytometry.

in: Advances in Protein Chemistry. Academic Press, 2001: 293-315

• Knowling S.
• et al.

Direct comparison of label-free biosensor binding kinetics obtained on the Biacore 8K and the Carterra LSA.

SLAS Discov. 2020; 25: 977-984

• Lofgren J.A.
• et al.

Comparing ELISA and surface plasmon resonance for assessing clinical immunogenicity of panitumumab.

J. Immunol. 2007; 178: 7467

• Khan S.H.
• et al.

A versatile method to measure the binding to basic proteins by surface plasmon resonance.

Anal. Biochem. 2012; 421: 385-390

• Brown M.E.
• et al.

Assessing the binding properties of the anti-PD-1 antibody landscape using label-free biosensors.

PLoS ONE. 2020; 15e0229206

• Beckmann R.
• et al.

DutaFabs are engineered therapeutic Fab fragments that can bind two targets simultaneously.

Nat. Commun. 2021; 12: 708

• Hunter S.A.
• et al.

An engineered ligand trap inhibits leukemia inhibitory factor as pancreatic cancer treatment strategy.

Commun. Biol. 2021; 4: 452

• Bee C.
• et al.

Exploring the dynamic range of the kinetic exclusion assay in characterizing antigen-antibody interactions.

PLoS One. 2012; 7: e36261

• Abdiche Y.
• et al.

Determining kinetics and affinities of protein interactions using a parallel real-time label-free biosensor, the Octet.

Anal. Biochem. 2008; 377: 209-217

• Petersen R.L.

Strategies using bio-layer interferometry biosensor technology for vaccine research and development.

Biosensors. 2017; 7: 49

• Leonard P.
• et al.

High throughput ranking of recombinant avian scFv antibody fragments from crude lysates using the Biacore A100.

J. Immunol. Methods. 2007; 323: 172-179

• Baeuerle P.A.
• et al.

Synthetic TRuC receptors engaging the complete T cell receptor for potent anti-tumor response.

Nat. Commun. 2019; 10: 2087

• Liu Y.
• et al.

Chimeric STAR receptors using TCR machinery mediate robust responses against solid tumors.

Sci. Transl. Med. 2021; 13

• Bloemberg D.
• et al.

A high-throughput method for characterizing novel chimeric antigen receptors in Jurkat cells.

Mol. Ther. Methods Clin. Dev. 2020; 16: 238-254

• Lever M.
• et al.

Phenotypic models of T cell activation.

Nat. Rev. Immunol. 2014; 14: 619-629

• Shakiba M.
• et al.

The impact of TCR affinity on T cell differentiation and dysfunction in tumors.

J. Immunol. 2018; 200: 57.24

• Stone J.D.
• et al.

T-cell receptor binding affinities and kinetics: impact on T-cell activity and specificity.

Immunology. 2009; 126: 165-176

• Moghimi B.
• et al.

Preclinical assessment of the efficacy and specificity of GD2-B7H3 SynNotch CAR-T in metastatic neuroblastoma.

Nat. Commun. 2021; 12: 511

• Radhakrishnan S.V.
• et al.

CD229 CAR T cells eliminate multiple myeloma and tumor propagating cells without fratricide.

Nat. Commun. 2020; 11: 798

• Park S.
• et al.

Micromolar affinity CAR T cells to ICAM-1 achieves rapid tumor elimination while avoiding systemic toxicity.

Sci. Rep. 2017; 7: 14366

• Laustsen A.H.
• et al.

In vivo neutralization of dendrotoxin-mediated neurotoxicity of black mamba venom by oligoclonal human IgG antibodies.

Nat. Commun. 2018; 9: 3928

Biacore Assay Handbook, GE Healthcare Life Sciences.

• Rich R.L.
• Myszka D.G.

Survey of the year 2007 commercial optical biosensor literature.

J. Mol. Recognit. 2008; 21: 355-400

• Vokali E.
• et al.

Lymphatic endothelial cells prime naïve CD8+ T cells into memory cells under steady-state conditions.

Nat. Commun. 2020; 11: 538

• Joshi N.S.
• Kaech S.M.

Effector CD8 T cell development: a balancing act between memory cell potential and terminal differentiation.

J. Immunol. 2008; 180: 1309

• Robbins P.F.
• et al.

Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions.

J. Immunol. 2008; 180: 6116

• Zhao Y.
• et al.

High-affinity TCRs generated by phage display provide CD4+ T cells with the ability to recognize and kill tumor cell lines.

J. Immunol. 2007; 179: 5845

• Carter P.
• et al.

Humanization of an anti-p185HER2 antibody for human cancer therapy.

Proc. Natl. Acad. Sci. U. S. A. 1992; 89: 4285-4289

• Schier R.
• et al.

Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site.

J. Mol. Biol. 1996; 263: 551-567

• Heitner T.
• et al.

Selection of cell binding and internalizing epidermal growth factor receptor antibodies from a phage display library.

J. Immunol. Methods. 2001; 248: 17-30

• Jin M.
• et al.

Directed evolution to probe protein allostery and
integrin I domains of 200,000-fold higher affinity.

Proc. Natl. Acad. Sci. 2006; 103: 5758

• Figini M.
• et al.

Panning phage antibody libraries on cells: isolation of human Fab fragments against ovarian carcinoma using guided selection.

Cancer Res. 1998; 58: 991-996

• Yang J.
• et al.

Therapeutic potential and challenges of targeting receptor tyrosine kinase ROR1 with monoclonal antibodies in B-cell malignancies.

PLoS One. 2011; 6e21018